Olin schedules third-quarter 2026 earnings call
Bitget2026/10/05 20:06Olin schedules a third-quarter 2026 earnings conference call for Oct. 30, 2026 at 10:00 a.m. ET. Third-quarter 2026 results release set for Oct. 29, 2026, post-close, with financial statements, segment data, slides. Webcast runs Oct. 30 via https://app.webinar.net/zYpbyYGxZk4 or www.olin.com; replay available for one year. Telephonic replay starts Oct. 30, 2026 at 12:00 p.m. ET; available for seven days. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olin Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610051605PR_NEWS_USPR_____NY63704) on October 05, 2026, and is solely responsible for the information contained therein.
- Olin schedules a third-quarter 2026 earnings conference call for Oct. 30, 2026 at 10:00 a.m. ET.
- Third-quarter 2026 results release set for Oct. 29, 2026, post-close, with financial statements, segment data, slides.
- Webcast runs Oct. 30 via https://app.webinar.net/zYpbyYGxZk4 or www.olin.com; replay available for one year.
- Telephonic replay starts Oct. 30, 2026 at 12:00 p.m. ET; available for seven days.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
